RyR2-targeting therapy prevents left ventricular remodeling and ventricular tachycardia in post-infarction heart failure.
Fujii S, Kobayashi S, Chang Y, Nawata J, Yoshitomi R, Tanaka S, Kohno M, Nakamura Y, Ishiguchi H, Suetomi T, Uchinoumi H, Oda T, Okuda S, Okamura T, Yamamoto T, Yano M.
Fujii S, et al. Among authors: yano m.
J Mol Cell Cardiol. 2023 May;178:36-50. doi: 10.1016/j.yjmcc.2023.03.007. Epub 2023 Mar 23.
J Mol Cell Cardiol. 2023.
PMID: 36963751